In addition, TIE1 has been shown to promote cisplatin resistance in ovarian cancer by upregulating xeroderma pigmentosum complementation group C (XPC)-mediated nucleotide excision repair (NER), decreasing cell sensitivity to cisplatin 31. Here, XPC is linked to ovarian cancer.